Firstly, the activation of phosphatase and tension homologs (PTEN) predicts inhibitory effect of trastuzumab, whereas PI3K pathway activation through PTEN loss and PIK3CA mutation confers trastuzumab resistance in breast cancer (45–49). The gene discussed is PTEN; the disease is breast cancer.